Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients

Dario Cattaneo, Diego Ripamonti, Sara Baldelli, Valeria Cozzi, Francesca Conti, Emilio Clementi

Research output: Contribution to journalArticlepeer-review


Raltegravir (RAL) is primarily metabolized by uridine diphosphate- glucorunosyl transferase 1A1 (UGT1A1). Atazanavir (ATV), a strong inhibitor of UGT1A1, has been shown to increase plasma concentrations of RAL by approximately 50% in healthy volunteers. However, the extent of this interaction has not been studied in HIV-infected patients. A pharmacokinetic study was performed in 22 HIV-infected adults treated with 400 mg RAL plus 300 mg ATV 300 twice a day. Both drugs showed high pharmacokinetic variability (RAL AUC0-12 7649 ± 4862 ng*h/mL; ATV AUC0-12 = 19237 ± 13136 ng*h/mL). Notably, RAL trough concentrations were significantly higher compared with those measured in HIV subjects (n = 24) on RAL plus nucleoside reverse transcriptase inhibitors (506 ± 411 versus 177 ± 262 ng/mL, P <0.01). A significant correlation was found between RAL and ATV area under the curve (AUC) (r = 0.611, P = 0.005). Notably, patients with ATV AUC0-12 above the mean or with concentrations exceeding the half maximal inhibitory concentration for UGT1A1 had twofold higher RAL AUCs compared with patients with lower ATV exposure. Coadministration of ATV significantly increased plasma concentrations of RAL, especially in HIV-1-infected patients exposed to high concentrations of the protease inhibitor. This pharmacokinetic drug interaction could be handled by routine measurements of ATV trough concentrations and by the assessment of plasma RAL concentrations 2 to 3 hours after the morning drug intake.

Original languageEnglish
Pages (from-to)782-786
Number of pages5
JournalTherapeutic Drug Monitoring
Issue number6
Publication statusPublished - Dec 2010


  • atazanavir
  • HIV
  • pharmacokinetics
  • raltegravir
  • therapeutic drug monitoring

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients'. Together they form a unique fingerprint.

Cite this